The ACTA2 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa cell line, engineered to disrupt the ACTA2 gene encoding alpha-smooth muscle actin (??-SMA). This product provides a pooled population of cells with heterogeneous ACTA2 gene modifications achieved via CRISPR/Cas9-mediated gene disruption, serving as a loss-of-function model for studying ??-SMA-dependent processes. The polyclonal format preserves genetic diversity while eliminating target protein expression across the population, enabling robust analysis of ACTA2 function in a widely utilized human epithelial carcinoma background.
HeLa cells are an aneuploid epithelial cell line originally isolated from a cervical adenocarcinoma of Henrietta Lacks in 1951. They harbor integrated human papillomavirus 18 (HPV-18) sequences and exhibit a high proliferative index, making them a staple in biomedical research for cancer biology, signal transduction, and cytoskeletal studies. The HeLa line??s well-characterized genetics and adaptability to genetic manipulation render it an ideal host for generating ACTA2 knockout models to investigate processes such as cell motility, adhesion, and mechanotransduction in a carcinoma context.
The ACTA2 gene product, ??-SMA, is a filamentous actin isoform that drives cell contraction, motility, and cytoskeletal integrity. Its transcription is controlled by TGF-??1 via Smad2/3 and by SRF in complex with myocardin, downstream of RhoA/ROCK1. YAP and TAZ mechanotransducers co-regulate ACTA2 expression in response to matrix stiffness. Following translation, ??-SMA polymerizes into actin stress fibers and binds myosin II to generate contractile force, while linking to focal adhesions through talin and integrin ??1. This network activates focal adhesion kinase (FAK) and promotes production of extracellular matrix proteins like collagen I, reinforcing actomyosin-dependent signaling and tissue remodeling.
Disruption of ACTA2 in HeLa cells abrogates ??-SMA expression, thereby perturbing actomyosin contractility, focal adhesion assembly, and YAP/TAZ-mediated mechanosignaling. Given that ??-SMA is a hallmark of myofibroblast differentiation and is frequently upregulated in cancer-associated fibroblasts and invasive carcinoma cells, this knockout model enables dissection of the molecular requirements for cytoskeletal remodeling and TGF-??-driven epithelial-mesenchymal transition-like phenotypes. In a HeLa background, which lacks endogenous ACTA2 expression under basal conditions, inducible or ectopic expression analyses can be paired with knockout populations to delineate ??-SMA-specific contributions to migration, invasion, and matrix remodeling independent of other actin isoforms.
Researchers can employ these ACTA2 Knockout HeLa Polyclonal Cells in a variety of experimental workflows, including scratch wound healing and transwell migration assays to quantify cell motility, immunofluorescence staining with phalloidin to visualize F-actin organization, and collagen contraction assays to assess matrix remodeling. The model is also suited for phospho-proteomics profiling of TGF-??1-stimulated Smad2/3 phosphorylation, co-immunoprecipitation of ??-SMA binding partners such as tensin and p130Cas, and RNA sequencing to map ACTA2-dependent transcriptomes. These cells facilitate drug screening for modulators of fibrotic disorders, cancer metastasis, and vascular pathologies. For further information or technical support, please contact Ascent Research.
